Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. - Wikidata - awgldk - TriplyDB

Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer.

Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer.

http://www.wikidata.org/entity/Q34900010

about

Metabolism of vertebrate amino sugars with N-glycolyl groups: elucidating the intracellular fate of the non-human sialic acid N-glycolylneuraminic acid Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants Rules and exceptions: sialic acid variants and their role in determining viral tropism Structural Basis for Substrate Specificity and Mechanism of N -Acetyl- d -neuraminic Acid Lyase from Pasteurella multocida Crystallographic and Glycan Microarray Analysis of Human Polyomavirus 9 VP1 Identifies N-Glycolyl Neuraminic Acid as a Receptor Candidate Human risk of diseases associated with red meat intake: Analysis of current theories and proposed role for metabolic incorporation of a non-human sialic acid Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity.Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer LC-MS analysis of polyclonal human anti-Neu5Gc xeno-autoantibodies immunoglobulin G Subclass and partial sequence using multistep intravenous immunoglobulin affinity purification and multienzymatic digestion.N-glycan Cryptic Antigens as Active Immunological Targets in Prostate Cancer Patients.Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.Sialic acid speciation using capillary electrophoresis: optimization of analyte derivatization and separation.Glyco-epitope Diversity: An Evolving Area of Glycomics Research and Biomarker Discovery.A red meat-derived glycan promotes inflammation and cancer progression A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease Exploration of sialic acid diversity and biology using sialoglycan microarrays.A sialylated glycan microarray reveals novel interactions of modified sialic acids with proteins and viruses.Competition between serum IgG, IgM, and IgA anti-glycan antibodies Protein glycosylation in cancer.Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays.Sequential One-Pot Multienzyme Chemoenzymatic Synthesis of Glycosphingolipid Glycans.Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.Metabolism of vertebrate amino sugars with N-glycolyl groups: mechanisms underlying gastrointestinal incorporation of the non-human sialic acid xeno-autoantigen N-glycolylneuraminic acid.Factors Affecting Anti-Glycan IgG and IgM Repertoires in Human Serum.Sialic acid metabolism and sialyltransferases: natural functions and applications.L1CAM from human melanoma carries a novel type of N-glycan with Galβ1-4Galβ1- motif. Involvement of N-linked glycans in migratory and invasive behaviour of melanoma cells.Glycoprotein disease markers and single protein-omics Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts.Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.Involvement of a non-human sialic Acid in human cancer.Complexity and Diversity of the Mammalian Sialome Revealed by Nidovirus Virolectins Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation.Characterization of immunoglobulin by mass spectrometry with applications for the clinical laboratory.Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.Sialic acids in cancer biology and immunity.The tumor antigen N-glycolyl-GM3 is a human CD1d ligand capable of mediating B cell and natural killer T cell interaction.Structure aided design of a Neu5Gc specific lectin.A rationally designed peptidomimetic biosensor for sialic acid on cell surfaces.

P2860

Q24338142-0DDB20EA-C8E9-48BD-919D-2BC92B078EB5 Q26775033-649E9522-7696-480E-BB93-AD60AF3B10F0 Q26865451-BB5C9E07-F621-4954-B782-2C9BF5CD8BFF Q27680435-DB4B121F-7255-435A-AA09-CBE943B0473C Q27682301-1DC8D3B6-9454-43B3-AA55-01D13F64EB16 Q30248988-E1DF2649-7E8A-4ECF-950F-BDC124704CEA Q33641923-B098A303-DCB7-44A8-A2A8-36A4D51DBB33 Q34069601-18DB4FE9-5342-4051-A0F5-8143F3596BDA Q34080004-35720E9D-EC8B-40CC-AA84-AF20489E4BC5 Q34280520-3561C55D-F940-4DF9-912F-355F7E5D5580 Q34315003-E608FC00-3A91-4EB1-8F44-BB2CF996592C Q34383299-4D2ACE91-B166-4DD1-9897-49704F75283C Q34449556-FA5B31C3-FEB1-413C-A2D8-E197224D99A9 Q34455992-B54B7000-22F3-4B42-9127-DF8007F74776 Q34631810-20F5EEE2-5C5D-4540-A195-B0C9AAC068F9 Q34772126-A1882375-3DCA-4AB5-8516-04C1D74A6B01 Q35213210-C47DA349-71F7-4321-A812-625E959EB1F3 Q35217313-0FD40E2E-3ACD-4CA7-9F84-372907412B64 Q35413473-96D33937-C7AD-4FBD-9E3E-D9B70615ECEE Q36080527-6CF3437C-95D4-451A-9D7A-94C40A47FEDB Q36162313-1B09679F-6078-401A-B680-1C64DBAC598C Q36169039-EF74F8DE-175C-4CD1-97B7-34AB14786093 Q36217161-55FFA5F8-DA2E-4F5C-A415-F29AFE5120CF Q36499916-72B8E46B-D334-4FF5-AE98-CA3F2C75E9E0 Q36501918-06B3D991-9099-4771-ACD4-F4A98D97A9E1 Q36710853-B3F154E8-783C-4B05-B91C-9C0AA2BD6C80 Q36742398-68803DF4-B8F8-4066-B769-A6A49BE76908 Q37011364-EB05E8ED-7A7C-4EF7-AD1B-849FB68073B3 Q37196570-71AF4EBB-96D1-461A-B281-98EEC4682B95 Q37512647-876CC66A-7F8E-432B-B6BB-B197C6D96A27 Q37592596-3B8F16E9-F3E1-460B-8649-7F0E37368C05 Q37625056-03220810-4DB6-48B9-9117-E28E5B010B5C Q37725333-168C5DB1-060B-42D4-BF9E-68FE707CF562 Q38012151-9B4D0CC5-E9C2-4E4E-A740-B6D74EEA8275 Q38155231-EAAEE638-7AF5-4058-9466-4EA0CCBEE7E2 Q38285397-CEA4CB2B-2286-4B26-81A1-06ECF64F0838 Q38620799-A6F70AD0-5B0E-4DB6-97E2-351604C65536 Q38786934-20749DA5-4489-47E0-B431-6D0C3707B88E Q38803207-57136811-BE3B-4BDD-BB64-0490202CF1F9 Q38887946-CE81B057-0C76-4918-8B52-7FB43D023B40

P2860

Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer.

http://www.wikidata.org/entity/Q34900010

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Human xeno-autoantibodies agai ...... immunotherapeutics in cancer.

@ast

Human xeno-autoantibodies agai ...... immunotherapeutics in cancer.

@en

Human xeno-autoantibodies agai ...... immunotherapeutics in cancer.

@nl

type

label

Human xeno-autoantibodies agai ...... immunotherapeutics in cancer.

@ast

Human xeno-autoantibodies agai ...... immunotherapeutics in cancer.

@en

Human xeno-autoantibodies agai ...... immunotherapeutics in cancer.

@nl

prefLabel

Human xeno-autoantibodies agai ...... immunotherapeutics in cancer.

@ast

Human xeno-autoantibodies agai ...... immunotherapeutics in cancer.

@en

Human xeno-autoantibodies agai ...... immunotherapeutics in cancer.

@nl

P1433

Q34900010-90BDFD7E-4EB5-4750-871B-E58C8D8DF0F7

P1476

Q34900010-A3739C94-8490-41DE-9775-A5432893B8E3

P2093

Q34900010-09CECDF2-810E-4104-A7D0-3125BAEFE997

Q34900010-0B58130D-09C0-4C87-8C7C-BA8C98CBD759

Q34900010-3707F207-9DE1-42AA-B79F-0B3F385A407E

Q34900010-3AFC6E60-3878-4B68-BEFB-71B529AF7690

Q34900010-547923C5-CBC4-425A-B0B4-264E02EF7FE0

Q34900010-54E5DF81-AF20-4607-85E9-3E9B423FF608

Q34900010-64DE2A13-BE0A-48F1-A66D-B8B0503FAA33

Q34900010-70A586EB-4C07-432D-9A35-59CE2C28998F

Q34900010-76AA5CD5-FD3C-4BB3-AC6B-1626D4D1B8B2

Q34900010-78D9FF4F-12CA-4278-BD5A-44E8B1D42928

P2860

Q34900010-00B073D0-283C-429F-8C76-129D38F20860

Q34900010-041F0749-3D9F-477F-AB97-D75CF5192C01

Q34900010-04604908-5D67-4384-B5F3-3D03624FF541

Q34900010-0A7FE9A6-3335-4291-BB21-71A072713805

Q34900010-0CBBBB16-2E8C-4B0E-B11D-4AAB54DCD879

Q34900010-117607F7-F771-4C9A-8262-2FBA7EB41EAA

Q34900010-12AC188C-DF78-43C6-8C1F-2507E90EBA69

Q34900010-19AA457D-BEB0-4BB5-8B7B-C6D207E03E77

Q34900010-26A96234-FCA4-4F82-9157-D428DEE14557

Q34900010-2C079B19-85EE-4CE9-8416-A25E9939BE6C

P304

Q34900010-42B87BB5-C832-4948-BD41-46EBCDF3A14B

P31

Q34900010-5F11B8C1-1FEA-4B81-BB37-CE5F20B84E36

P356

Q34900010-047C0654-DA34-413F-9EFD-C4A29E9268BC

P407

Q34900010-8266EA71-DAC2-4B69-8005-A18BA71F21C3

P433

Q34900010-FCC3D393-A151-4B5B-BA71-57D0B22DF39F

P478

Q34900010-F87B225A-0F3B-4C64-AE79-A55B6E9C4021

P50

Q34900010-5DC344B4-D154-47FC-87D6-A9F0C88D2259

P577

Q34900010-27068359-F138-4E39-905A-D22117CBA450

P698

Q34900010-CED6B469-8E05-4ADE-A9C4-2A7CC65199CF

P921

Q34900010-30328EA8-0C31-4BBD-8631-FA9FF5251AC3

Q34900010-9F0BCC37-4584-4B48-94AD-FEF1C712DF02

Q34900010-EA1AC25E-4077-45E2-A85F-37FE887CCA33

P932

Q34900010-FDCDFC30-5A53-4CCF-AE39-5D6333BC5E2C

P356

0008-5472.CAN-10-4102

P1433

Cancer Research

P1476

Human xeno-autoantibodies agai ...... d immunotherapeutics in cancer

@en

P2093

Ajit Varki

http://www.w3.org/2001/XMLSchema#string

Darius Ghaderi

http://www.w3.org/2001/XMLSchema#string

Dinorah Friedmann-Morvinski

http://www.w3.org/2001/XMLSchema#string

Hai Yu

http://www.w3.org/2001/XMLSchema#string

Harshal A Chokhawala

http://www.w3.org/2001/XMLSchema#string

Inder M Verma

http://www.w3.org/2001/XMLSchema#string

Karen Messer

http://www.w3.org/2001/XMLSchema#string

Minya Pu

http://www.w3.org/2001/XMLSchema#string

Nancy Hurtado-Ziola

http://www.w3.org/2001/XMLSchema#string

Oded Singer

http://www.w3.org/2001/XMLSchema#string

P2860

A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase

Screening for breast cancer: an update for the U.S. Preventive Services Task Force

Colloquium paper: uniquely human evolution of sialic acid genetics and biology

One-pot three-enzyme chemoenzymatic approach to the synthesis of sialosides containing natural and non-natural functionalities

Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid

Biomarkers in cancer staging, prognosis and treatment selection

Genetically altered mice with different sialyltransferase deficiencies show tissue-specific alterations in sialylation and sialic acid 9-O-acetylation

Screening and prostate-cancer mortality in a randomized European study

N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution

A multifunctional Pasteurella multocida sialyltransferase: a powerful tool for the synthesis of sialoside libraries.

P304

3352-3363

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-4102

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21505105

http://www.w3.org/2001/XMLSchema#string

P921

P932

3085609

http://www.w3.org/2001/XMLSchema#string